Intellia Therapeutics Inc (NASDAQ:NTLA) saw unusually-strong trading volume on Thursday . Approximately 552,077 shares traded hands during mid-day trading, an increase of 114% from the previous session’s volume of 258,064 shares.The stock last traded at $21.98 and had previously closed at $21.08.

A number of research analysts have recently commented on NTLA shares. Credit Suisse Group AG started coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They issued an “outperform” rating and a $39.00 target price for the company. Jefferies Group initiated coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They set a “hold” rating and a $33.00 price objective for the company. Wedbush initiated coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They set an “outperform” rating and a $38.00 price objective for the company. Leerink Swann initiated coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They set a “market perform” rating and a $32.00 price objective for the company. Finally, Zacks Investment Research cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 3rd. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $35.50.

The stock’s 50-day moving average price is $19.46 and its 200 day moving average price is $23.00. The company’s market capitalization is $753.38 million.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.